ECP
PTX

Empyrean Capital Partners’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Empyrean Capital Partners’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,500
Closed -$44K – 107
2015
Q4 		$44K Hold
1,500
– – ﹤0.01% 68
2015
Q3 		$47K Hold
1,500
– – ﹤0.01% 52
2015
Q2 		$89K Buy
+1,500
New +$106K ﹤0.01% 57

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Empyrean Capital Partners's PTX Position: Q1 2016 in Review

Empyrean Capital Partners sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2016, closing a stake of 1,500 shares — an estimated $44K sold.

Empyrean Capital Partners first reported a position in PTX in Q2 2015 and held it in 3 quarters. The position peaked at $89K in Q2 2015. 88 funds tracked by Wall St. Rank hold PTX as of Q1 2016.

  • Empyrean Capital Partners reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2016 after selling out during the quarter.
  • Empyrean Capital Partners sold 1,500 Pernix Therapeutics Holdings, Inc. shares in Q1 2016, an estimated $44K.
  • Empyrean Capital Partners first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 3 quarters.
  • Empyrean Capital Partners's Pernix Therapeutics Holdings, Inc. position peaked at $89K in Q2 2015.
  • 88 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2016.

Based on Empyrean Capital Partners's 13F filing for Q1 2016, filed 16 May 2016.